ImmunityBio, Inc. (IBRX)
Sous-évaluéFondamental
46
Prix
$9.44
Capitalisation boursière
$10.00B
Partie 1 · Ce que vaut l'entreprise
Vue d'ensemble
ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors. Its lead biologic product candidate includes Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors; and 3M-052, a synthetic TLR7/8 agonist and 3M-052 formulations and related technology. The company has collaboration agreements with National Cancer Institute; Serum Institute of India Private Limited; and BeOne Medicines Ltd. It has license agreement with 3M Innovative Properties Company and Access to Advanced Health Institute. ImmunityBio, Inc. is based in San Diego, California.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Bilan & Liquidités
Chiffre d'affaires
$166M
12 derniers mois (au 30/06/2026)
Résultat net
$-992M
12 derniers mois (au 30/06/2026)
Flux de trésorerie libre
$-309M
Capitaux propres totaux
$-500M
Passif total
$1.00B
Ratio de liquidité général
5.72
Couverture des intérêts
4.21
Dette/EBITDA
-
Bénéfice par action
Chiffre d'affaires & Résultat net
Flux de trésorerie libre
Décomposition du résultat
État historique
Marges dans le temps
La dette dans le temps
Le poids de la dette
Grille de la croissance
Croissance — Chiffre d'affaires
Estimation de la juste valeur
Juste valeur
$12.75
Prix actuel
$9.44
Marge de sécurité
+26.0%
Fourchette de juste valeur
$12.11 - $13.39
Écart entre les méthodes de valorisation utilisées, pas un intervalle de confiance calibré statistiquement.
Méthodes d'estimation
Indicateurs de valorisation
Ratio P/E
-
ROE
70.2%
Ratio P/B
-
P/FCF
-
Marge brute
99.3%
ROIC
-36.0%
Radar de rentabilité
Création de valeur (avantage concurrentiel)
ROIC
-36.0%
WACC
7.6%
ROIC − WACC
-43.6 pp
Le ROIC est inférieur au coût du capital — l'entreprise détruit de la valeur pour chaque dollar investi.
Critères d'analyse fondamentale
Réussi (9)
- EPS shows upward trend
- Gross Margin 99.3%
- Current Ratio
- Interest Coverage
- Low reliance on intangibles
- Revenue Growth 5Y 184.3%
- Analyst Consensus 90% Buy
- Net Margin Trend -598.6% vs -648.6%
- Piotroski F-Score 5/9
Échoué (9)
- Price CAGR 4.20%
- ROIC -36.1%
- Operating Margin -151.9%
- Positive Free Cash Flow
- Return on Tangible Assets
- DCF valuation (Unknown)
- ROE -193.3%
- Earnings Surprise avg -19.4%
- Share Dilution 38.6%
Indisponible (9)
- P/FCF NaN
- P/B Ratio NaN
- Dividend Payout NaN%
- Debt/Equity ratio
- CapEx intensity
- Debt/EBITDA
- Price below Graham Number
- PEG Ratio (need PE > 0 and growth > 0)
- Earnings Quality (OCF/Net Income)
Score F de Piotroski
Signaux mixtes : certains domaines nécessitent attention
Qualité des bénéfices
Qualité faible : examiner la comptabilité
Dilution du capital
Émission de nouvelles actions, diluant la participation
Participations institutionnelles
Gouvernance
Équipe dirigeante
| Nom | Titre | Âge |
|---|---|---|
| Dr. Patrick Soon-Shiong F.A.C.S., FRCS (C), M.D., M.S., M.Sc. | Founder, Executive Chairman and Global Chief Scientific & Medical Officer | 72 |
| Mr. Richard Gerald Adcock | President, CEO & Director | 56 |
| Mr. David C. Sachs | Chief Financial Officer | 47 |
| Ms. Regan J. Lauer | Chief Accounting Officer | 55 |
| Dr. Barry J. Simon M.D. | Chief Corporate Affairs Officer & Director | 60 |
| Dr. Enrique Diloné Ph.D., RAC | Chief Technology Officer | 58 |
| Ms. Sarah Singleton | Chief Communications Officer & Head of Patient Advocacy | - |
| Ms. Emily Arison | Senior Vice President of Human Resources | - |
| Dr. Leonard S. Sender M.D. | Chief Medical Officer of Liquid Tumors & Cell Therapy | - |
| Dr. Sandeep K. Reddy M.D. | Chief Medical Officer | - |
Risque d'audit
6
Risque du conseil
8
Risque de rémunération
9
Risque droits des actionnaires
6
Partie 2 · Le prix et le moment d'entrer
Cette partie ne dit pas si l'entreprise vaut la peine : elle aide à choisir quand l'acheter, une fois que les fondamentaux vous ont convaincu. À l'intérieur : analyse technique, potentiel, baisses historiques, exposition gamma.
Documents
- Voir le document
Rapport annuel (10-K)
Un aperçu annuel de l'activité, des résultats financiers et des risques de l'entreprise.
Déposé le 2026-02-23
- Voir le document
Rapport trimestriel (10-Q)
Une mise à jour de la performance financière des trois derniers mois.
Déposé le 2026-08-04
- Voir le document
Rapport d'événement important (8-K)
Un avis concernant un événement important, comme un changement de direction ou une annonce majeure.
Déposé le 2026-08-04
via SEC EDGAR
Historique des résultats
via SEC EDGAR
Latest News
Recent headlines for IBRX, sourced from Markets Gazette.
- 2/25/2026POSITIVEImmunityBio Supersedes Expectations With Fivefold Revenue Increase
ImmunityBio Inc. has significantly exceeded analyst expectations, driving a surge in its stock price due to exceptional financial results. Sales of its drug Anktiva demonstrated an impressive 750% increase, contributing to an overall fivefold revenue growth that comfortably beat estimates. This substantial revenue beat, coupled with a new strategic partnership in Saudi Arabia, fuels the company's future growth prospects. Investors should closely monitor the long-term impact of these sales figures and the partnership on ImmunityBio's trajectory within the biopharmaceutical sector.
- 2/23/2026POSITIVEStock Market Today, Feb. 23: ImmunityBio Surges After Anktiva Revenue Jumps 700%
ImmunityBio captured the market's attention on February 23, 2026, with its stock surging on extraordinary news: revenue from its flagship drug, Anktiva, jumped by a staggering 700%. This phenomenal figure overshadowed the company's current, albeit deep, operating losses. Investors are clearly betting on the long-term potential of the drug and the company's ambitious global expansion strategy. While the losses remain a factor to watch, the revenue growth trajectory suggests strong market adoption and a promising future. The market's reaction indicates that top-line growth is currently the most powerful catalyst for the stock's valuation, outweighing concerns about short-term profitability.
via Markets Gazette